Skinesa® Achieves No. 2 on 2025 Gator100 with 665% CAGR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Yahoo Finance
- Rapid Growth: Skinesa® achieved a remarkable 665% CAGR over the past three years, earning the No. 2 spot on the University of Florida's Gator100 list, which underscores its leadership and commitment to scientific excellence in the probiotic skincare industry.
- Market Expansion: This year, the company launched chewable skin probiotics for kids, which not only diversifies its product line but also enhances its competitive edge and market share in the skincare sector.
- Strengthened Partnerships: Skinesa® is reinforcing its collaborations with doctors and healthcare professionals to solidify its research position in the skincare industry, which will help enhance brand credibility and customer trust.
- Leadership Remarks: CEO Ryan Walters expressed that earning the No. 2 spot on the Gator100 is a tremendous honor, reflecting the company's values in innovation, leadership, and problem-solving, further motivating the team to pursue purposeful and integrity-driven growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SKIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SKIN
Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 1.510
Low
1.50
Averages
2.13
High
3.50
Current: 1.510
Low
1.50
Averages
2.13
High
3.50
About SKIN
The Beauty Health Company is a medical technology meets beauty company that delivers skin-health experiences. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. It specializes in skin health for all ages, genders, skin tones, and skin types. Its brands include Hydrafacial, SkinStylus, and Keravive. Hydrafacial created the category of hydradermabrasion with its patented delivery system that cleanses, extracts, and hydrates the skin with proprietary solutions and serums. SkinStylus specializes in nanoneedling and microneedling, where its products are designed to provide either a non-invasive (nanoneedling) or minimally invasive (microneedling) skin treatment to individuals. Keravive specializes in scalp health with its products that are designed to support the hair’s natural growth by cleansing, exfoliating, and hydrating the scalp and hair follicles.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
Continue Reading
Skinesa® Achieves No. 2 on 2025 Gator100 with 665% CAGR
- Rapid Growth: Skinesa® achieved a remarkable 665% CAGR over the past three years, earning the No. 2 spot on the University of Florida's Gator100 list, which underscores its leadership and commitment to scientific excellence in the probiotic skincare industry.
- Market Expansion: This year, the company launched chewable skin probiotics for kids, which not only diversifies its product line but also enhances its competitive edge and market share in the skincare sector.
- Strengthened Partnerships: Skinesa® is reinforcing its collaborations with doctors and healthcare professionals to solidify its research position in the skincare industry, which will help enhance brand credibility and customer trust.
- Leadership Remarks: CEO Ryan Walters expressed that earning the No. 2 spot on the Gator100 is a tremendous honor, reflecting the company's values in innovation, leadership, and problem-solving, further motivating the team to pursue purposeful and integrity-driven growth.
Continue Reading